The Nicotine Supply Chain Weaponization: How Geopolitics Is Reshaping the Global Nicotine Market

The nicotine product you use—whether a cigarette, a vape, a pouch, or a lozenge—is the endpoint of a global supply chain that crosses multiple borders, regulatory jurisdictions, and geopolitical fault lines. The tobacco leaf may be grown in Malawi, processed in India, blended in the Netherlands, and sold in Brazil. The vaping device may be assembled in Shenzhen from components manufactured across Guangdong province, shipped through Hong Kong, distributed through a warehouse in California, and sold in a convenience store in Texas. The nicotine used in pouches and pharmaceutical NRT may be extracted from tobacco in India or synthesized in a Chinese laboratory, then shipped to a formulation facility in Europe or the US. This supply chain is efficient, resilient, and almost entirely dependent on cross-border trade that is increasingly subject to geopolitical disruption.

The US-China trade tensions that escalated during the Trump administration and continued under Biden have directly affected the nicotine industry. Tariffs on Chinese imports, imposed in multiple rounds beginning in 2018, increased the cost of vaping hardware imported from Shenzhen, where approximately 90% of global vaping hardware is manufactured. The tariffs have had the effect of raising consumer prices, compressing retailer margins, and—in some cases—shifting manufacturing to alternative locations (Vietnam, Indonesia, Mexico) that lack the specialized ecosystem of Shenzhen's vaping industry but offer tariff avoidance. The supply chain disruption is not just an economic story. It's a public health story: the availability and affordability of vaping products—which are, for adult smokers trying to switch, a health intervention—is affected by trade policies that have nothing to do with public health.

The scarcity of pharmaceutical-grade nicotine during the COVID-19 pandemic revealed the fragility of the supply chain for nicotine replacement therapy. India and China, the two primary producers of nicotine USP (United States Pharmacopeia-grade nicotine used in NRT products), imposed export restrictions during the pandemic, prioritizing domestic pharmaceutical needs. The restrictions caused shortages of nicotine patches, gum, and lozenges in several countries—shortages that were largely invisible to the public but that disrupted the supply of cessation aids at a moment when smoking cessation was particularly urgent (smoking was identified early in the pandemic as a risk factor for severe COVID-19 outcomes). The episode highlighted the concentration of pharmaceutical nicotine production in two countries—a concentration that creates vulnerabilities that the public health community has not adequately addressed. Diversifying the supply chain for nicotine USP—including through the development of synthetic nicotine that does not depend on tobacco cultivation—is a strategic priority that has received far less attention than it deserves.

The geopolitical dimension of the nicotine supply chain extends beyond trade policy to include the enforcement of intellectual property rights, the regulation of cross-border e-commerce, and the use of supply-chain controls as instruments of foreign policy. The US FDA's import alerts—which allow the agency to detain shipments of products that appear to violate US regulations—have been used to block imports of unauthorized vaping products, but the volume of imports overwhelms the enforcement capacity. US Customs and Border Protection seizes a fraction of the unauthorized products entering the country. The rest enter through a combination of mislabeling (products declared as 'electronic components' or 'aromatherapy devices'), small-package shipping that avoids bulk-cargo scrutiny, and routing through third countries that have less restrictive customs enforcement. The supply chain is adaptive and resilient—characteristics that make it commercially efficient and regulatorily challenging in equal measure.

The potential for supply-chain weaponization—the use of supply-chain controls as instruments of geopolitical coercion—is a risk that the nicotine industry and its regulators have not adequately considered. China's dominance of vaping hardware manufacturing gives it a potential point of leverage over the global vaping market—a lever that has not been pulled but that exists. India's role as a major producer of pharmaceutical nicotine gives it similar leverage over the NRT supply chain. The dependence is not symmetric—the US and EU are major markets that China and India have commercial incentives to continue supplying—but it is real and it creates vulnerabilities that would become apparent in a geopolitical crisis. The diversification of the nicotine supply chain is not just an economic resilience strategy. It's a public health resilience strategy—ensuring that the products that smokers need to quit or switch remain available regardless of geopolitical developments.

The supply-chain perspective also illuminates the distributional consequences of nicotine policy. When the US imposes tariffs on Chinese vaping hardware, the cost is borne by American vapers—disproportionately former smokers who switched to vaping for health reasons—and the benefit (protection of domestic manufacturing) is minimal because there is almost no domestic vaping hardware manufacturing to protect. When India restricts the export of pharmaceutical nicotine, the cost is borne by smokers in importing countries who lose access to cessation aids, and the benefit (ensuring domestic supply of nicotine for Indian pharmaceutical needs) is legitimate but could be achieved through less disruptive means (strategic reserves, production diversification). The distributional consequences of supply-chain policies are rarely considered in the design of those policies. The nicotine supply chain is treated as a commercial matter. It is, in fact, a public health infrastructure—and its resilience deserves the same attention as the resilience of other public health supply chains (vaccines, essential medicines, medical equipment).

Shareable insight: The nicotine product you use has traveled through a supply chain that crosses multiple borders and is increasingly subject to geopolitical disruption—tariffs, export controls, supply-chain nationalism. The policies that affect this supply chain are rarely designed with public health in mind. But their public health consequences—in the availability and affordability of products that help smokers quit—are real and largely unacknowledged.